Reuters logo
BRIEF-Capricor Therapeutics plans to discuss with U.S. FDA potential product registration strategies for CAP-1002
May 31, 2017 / 11:08 AM / 4 months ago

BRIEF-Capricor Therapeutics plans to discuss with U.S. FDA potential product registration strategies for CAP-1002

May 31 (Reuters) - Capricor Therapeutics Inc:

* Capricor Therapeutics - co plans to discuss with U.S. FDA potential product registration strategies for cap-1002 in duchenne muscular dystrophy indication

* Formal meeting between Capricor & FDA is scheduled to be held by telephone in second half of June 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below